Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists probe Dopamine's role in epilepsy with yawn and blink test

NCT ID NCT01432821

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how the brain chemical dopamine behaves in people with idiopathic generalized epilepsy compared to healthy volunteers. Researchers measured yawning and blinking after giving a low dose of apomorphine, a drug that mimics dopamine. The goal was to understand brain differences, not to treat the condition. 31 people took part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

31 people

The number who actually took part.

Start date

Sep 2011

Finished

Dec 2014

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For patients: * Men and women aged between 18 and 40 * Person affiliated to social security or beneficiary of such a regime * idiopathic generalized epilepsy treated with lamotrigine, an association of lamotrigine, topiramate, levetiracetam, lamotrigine or levetiracetam alone (group patients) for at least 14 days without changing doses The idiopathic generalized epilepsy is defined by generalized seizures: generalized tonic-clonic seizures, absences or myoclonic seizures, excluding any other type of seizure, and electroencephalographic appearance following: presence of interictal EEG discharge generalized to type of spikes, spike-wave or wave polyspikes generalized, sporadic or rhythmic\> or = 3 Hz background activity is normal. For healthy volunteers: * Men and women aged between 18 and 40 * Person affiliated to social security or beneficiary of such a regime Exclusion Criteria: * Topic wrongly included * Deflecting protocol that can skew the primary endpoint * Primary endpoint missing * If the investigator considers the health of the subject is incompatible with the continuation of the study. Criteria for non-inclusion * For patients: * The presence of interictal focal discharges on EEG previous * The emergence of partial seizures * Restless Leg Syndrome * All non-antiepileptic treatment may affect levels of dopamine * Current use of illicit drugs. * A person deprived of liberty by judicial or administrative person being a measure of legal protection. * Pregnant, parturient, lactating mother. * For women, lack of effective contraception * For healthy volunteers: * Any medical treatment associated * Current use of illicit drugs * Pregnant, parturient, lactating mother * For women, lack of effective contraception * A person deprived of liberty by judicial or administrative person being a measure of legal protection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic generalized epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CIC Department - University Hospital of Grenoble

    La Tronche, Isere, 38700, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.